• To be able to use Response Evaluation Criteria in Solid Tumours (RECIST) for assessment of tumour response as (part of) an end point in the context of clinical trials

  • Awareness that RECIST is the result of an initiative to harmonise the definition of tumour response to establish a credible end point that can be used uniformly across centres in a multicentre trial, but also to compare results across clinical trials on different tumour types and treatment modalities

  • Recognition that RECIST was developed to be broadly applicable, ie, across different solid tumours, but can be of limited use in certain settings due to specificities of some tumour types; for these, alternative response criteria may exist

  • Appreciation that RECIST was developed primarily for assessing activity (in terms of tumour shrinkage) of cytotoxic agents, as an end point in phase II trials, but is increasingly used as an end point for treatment efficacy in phase III trials (progression-free survival based on RECIST assessments) of non-cytotoxic agents

  • Awareness that RECIST was developed for clinical trials; for the individual patient, treatment benefit should be based on medical judgement that results from a synthesis of clinical, imaging and laboratory data

  • Awareness of the existence of a dedicated website which addresses frequently asked questions (http://www.eortc.org/recist/)

  • Familiarity with RECIST 1.1

    • Difference between measurable and non-measurable disease

    • Difference between the evaluation of target and non-target lesions

    • Number of lesions to be assessed

    • How to integrate lymph nodes in the assessment

    • The role of confirmation of response

  • Ability to contribute in tumour board reviews with imaging specialists

  • Ability to use the RECIST for evaluating the response and to base further treatment or follow-up decisions upon